Allan Reine

Chief Financial Officer

Foghorn Therapeutics Inc.Prime Medicine, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 1 buy · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€130k

▼ Sales (0 ops.)

—

Latest filing published 22 May 2025 for Prime Medicine, Inc., €130k. Read the official filing

Filing timeline

BuySale

Allan Reine

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+149.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Allan Reine: trading record in brief

Allan Reine, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Foghorn Therapeutics Inc. and Prime Medicine, Inc. In total, 2 filings cover trades dated from 9 August 2021 to 21 May 2025.

The open-market record is one-sided, with 1 purchase worth €130k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 option exercise. Since January 2025: 1 purchase and no sales on the market.

The record was last updated on 22 May 2025 with an open-market purchase (€130k) in Prime Medicine, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.